Don't wait until manufacturing execution system (MES) configuration to answer these 7 questions. Define your manufacturing process before digitizing it.
- FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
- You Can't CAPA What You Can't Classify
- 6 Modeling Approaches That Make Complex Bioprocess Data Useful
- Building Trust In AI For Computerized System Validation
- A Gentler Cell Line Selection Method Using microRNA
- Controls For Retrieval-Augmented Generation In GxP
- Implementing AI Solutions In GMP While Managing Risk
GUEST COLUMNISTS
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
You Can't CAPA What You Can't Classify
An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
-
6 Modeling Approaches That Make Complex Bioprocess Data Useful
AI algorithms can reduce data dimensionality more faithfully by interpreting multivariate features relevant to prediction or control.
-
Building Trust In AI For Computerized System Validation
Using AI for CSV might feel like the students are grading their own papers. One consultant explains why it's not the same, namely, there are no subjective judgment calls.
-
A Gentler Cell Line Selection Method Using microRNA
Traditional selection stresses surviving cells. New research shows how structurally interacting RNA may use endogenous microRNA for a faster, nontoxic selection process.
-
Controls For Retrieval-Augmented Generation In GxP
Validation teams deal with inherent variability all the time. The same principles for GMP — think visual inspection — can apply to probabilistic AI systems.
-
Implementing AI Solutions In GMP While Managing Risk
When using artificial intelligence in GMP settings, risk management extends far beyond validation. This discussion explores moving AI solutions out of the pilot phase.
BIOSIMILAR WHITE PAPERS
-
Innovation In Filtration
Filtration removes contaminants to ensure safety and is essential in various applications, from lab-scale tasks to GMP production. Explore how its simplicity and reliability make it indispensable.
-
Biopharma Supply, Reimagined: Regional, Resilient Manufacturing4/1/2026
Persistent disruption is redefining biopharma supply chains. Explore how regional manufacturing, integrated risk management, and closer collaboration help build resilience and improve agility.
-
Digital Biomanufacturing, Now: From Digital Dreamer To Digital Doer3/24/2025
Discover how digital biomanufacturing is revolutionizing drug production by exploring strategies for integrating digital technologies to enhance efficiency and innovation in bioprocessing workflows.
-
Life Cycle Assessment Of Extended Use Strategies For Single-Use Assemblies4/17/2026
Examine how extending the use of single‑use assemblies can significantly reduce emissions, resource consumption, and waste in bioprocessing, offering a data‑backed path toward sustainability.
-
ADC Development Grows More Complex — SPR Insights Bring Clarity4/14/2026
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
High-Performing Ionizable Lipids For Controlled Nucleic Acid Delivery9/29/2026
Ionizable lipids are central to effective mRNA delivery, influencing potency, biodistribution, and toxicity. See why advancing delivery beyond the liver will require stronger structure-function insights.
BIOSIMILAR APP NOTES & CASE STUDIES
- Application Of A Dual Spiking Strategy In Viral Clearance Studies
- Aseptic Filling Solution Enhances Sterility Assurance for Pharma Manufacturer
- Customer Story: Emergent BioSolutions Enhances Aseptic Filling Process
- Comparing Process Development Approaches For Recombinant Proteins
- Virus Retention Performance Under Diverse Processing Conditions
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Waltz Health And Fresenius Kabi Expand Direct Access To Biosimilars Through Waltz Connect Platform
- The Biosimilars Forum Strongly Supports FDA's BsUFA IV Agreement To Strengthen Biosimilar Development And Review
- Sandoz Opens Advanced High-Volume Drug Substance Manufacturing Centre In Lendava, Significantly Strengthening In-House Capacity And Flexibility Across Leading European Biosimilar Network
- STADA And SBP Group Launch Strategic Biosimilars Partnership, Including A Biosimilar To Keytruda
- Meitheal Pharmaceuticals Announces FDA Approval Of High-Concentration Formulation Of YUSIMRY, A Biosimilar To Humira
- Teva Continues Biosimilar Momentum With U.S. FDA Approval Of DEGEVMA™ (denosumab-adet), A Biosimilar To Xgeva® (denosumab)
- AAM And Biosimilars Council Comment On GDUFA And BsUFA User Fee Negotiations And Reauthorization
- PhRMA Statement On The Biosimilar User Fee Act (BsUFA) IV Performance Goals Letter
NEWSLETTER ARCHIVE
- 10.01.26 -- Faster Paths To Biosimilar Equivalence
- 09.24.26 -- Navigating The Regulatory Space To Biosimilar Approval
- 09.17.26 -- Your Collaborator: mAb Productivity And Robustness
- 09.17.26 -- A Much-Improved Approach For Managing Safety Risks
- 09.16.26 -- Smarter Ways To Reduce Risk, Downtime, And Lifecycle Surprises